Strengths

High current and quick ratios indicate liquidity well above most development-stage biotech peers, supporting near-term operating flexibility despite ongoing losses.

Net debt to EBITDA remains modest versus many leveraged small-cap biopharma peers, limiting refinancing pressure and preserving balance-sheet optionality.

A positive cash conversion cycle suggests working-capital discipline relative to peers with longer cash burn cycles, which can modestly reduce funding strain.

The capital structure appears manageable for a pre-profit specialty pharma company, giving AQST more resilience than peers with tighter liquidity and heavier leverage.

Weaknesses

Return on invested capital is deeply negative, showing capital deployment is still destroying value versus profitable peers and limiting structural earnings power.

The absence of reported operating and gross margins signals an unproven commercial profit engine, leaving AQST behind peers with established margin profiles.

Negative debt-to-equity metrics reflect an equity base under pressure, which weakens financial flexibility relative to better-capitalized specialty pharma peers.

A 30-day cash conversion cycle is not enough to offset persistent unprofitability, so peers with positive cash generation retain a clear structural advantage.

Opportunities

If commercialization scales, AQST can convert its liquidity cushion into operating leverage faster than peers already constrained by debt service or thin cash balances.

Specialty pharma peers with narrower product focus may face slower portfolio expansion, creating room for AQST to improve relative positioning through execution.

A stronger balance sheet than many small-cap peers can support targeted investment in launch, manufacturing, or lifecycle activities that widen future margin potential.

As the company matures, any sustained improvement in capital efficiency would have outsized peer-relative impact because current returns remain deeply negative.

Threats

Peers with approved, cash-generating products can outcompete AQST on margin durability, making its current loss profile a structural disadvantage.

If commercialization or pipeline execution slips, the company’s negative returns leave less buffer than peers with recurring profitability and stronger reinvestment capacity.

Specialty pharma competition can compress pricing and limit uptake, which would hurt AQST more than larger peers with broader portfolios and scale advantages.

Because profitability is not yet established, any funding market tightening would weigh more heavily on AQST than on peers with internal cash generation.

Overall Score

AQST’s liquidity and manageable leverage provide some resilience versus peers, but deeply negative returns and an unproven profit model keep its structural positioning below stronger specialty pharma competitors.